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CADASIL (cerebral autosomal–dominant arteriopathy with subcortical infarcts and leukoencephalopathy), the 
most common heritable cause of stroke and vascular demen-
tia in adults, is a rare autosomal–dominant disorder caused 
by mutations in the 33-exon NOTCH3 gene on chromosome 
19p13.1.1–5 Clinically, CADASIL is characterized by recurrent 
ischemic events starting in mid-adulthood, with an average 
incidence rate of stroke of 10.4/100 person-years.3 Although 
Background and Purpose—Cerebral autosomal–dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), a rare autosomal dominant disorder caused by NOTCH3 mutations, is characterized by vascular smooth 
muscle and endothelial cells abnormalities, altered vasoreactivity, and recurrent lacunar infarcts. Vasomotor function 
may represent a key factor for disease progression. Tetrahydrobiopterin, essential cofactor for nitric oxide synthesis in 
endothelial cells, ameliorates endothelial function. We assessed whether supplementation with sapropterin, a synthetic 
tetrahydrobiopterin analog, improves endothelium-dependent vasodilation in CADASIL patients.
Methods—In a 24-month, multicenter randomized, double-blind, placebo-controlled trial, CADASIL patients aged 30 to 65 
years were randomly assigned to receive placebo or sapropterin 200 to 400 mg BID. The primary end point was change 
in the reactive hyperemia index by peripheral arterial tonometry at 24 months. We also assessed the safety and tolerability 
of sapropterin. Analysis was done by intention-to-treat.
Results—The intention-to-treat population included 61 patients. We found no significant difference between sapropterin 
(n=32) and placebo (n=29) in the primary end point (mean difference in reactive hyperemia index by peripheral arterial 
tonometry changes 0.19 [95% confidence interval, −0.18, 0.56]). Reactive hyperemia index by peripheral arterial tonometry 
increased after 24 months in 37% of patients on sapropterin and in 28% on placebo; however, after adjustment for age, sex, 
and clinical characteristics, improvement was not associated with treatment arm. The proportion of patients with adverse 
events was similar on sapropterin and on placebo (50% versus 48.3%); serious adverse events occurred in 6.3% versus 
13.8%, respectively.
Conclusions—Sapropterin was safe and well-tolerated at the average dose of 5 mg/kg/day, but did not affect endothelium-
dependent vasodilation in CADASIL patients.
Clinical Trial Registration—URL: https://www.clinicaltrialsregister.eu. Unique identifier: 2007-004370-55.   
(Stroke. 2014;45:2959-2966.)
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extent and mode of disease progression vary largely, many 
patients with CADASIL eventually develop severe motor 
disability, pseudobulbar palsy, and subcortical dementia. 
Treatment of CADASIL is largely empirical at present and 
based on current cerebrovascular disease management.1
NOTCH3 encodes for a transmembrane receptor of a signal-
ing pathway that exerts a central role in vascular development 
and is prevalently expressed in vascular smooth muscle cells 
and capillary pericytes in the adult brain.5 Vasomotor function 
may play a fundamental role for the eventual development 
of ischemic lesions. In transgenic mice expressing mutant 
NOTCH3 in vascular smooth muscle cells, impaired cerebral 
blood flow autoregulation and increased myogenic tone predate 
the appearance of vascular abnormalities,6 whereas in patients, 
cerebral blood flow and metabolism are decreased early in the 
clinical course of CADASIL.7,8 Structural abnormalities in 
CADASIL patients encompass lumen narrowing of the arteri-
oles, destruction of vascular smooth muscle cell anchorage to 
the extracellular matrix, and alterations in the cytoskeleton and 
in the endothelial cells.9,10 Moreover, capillaries, which have a 
major role in blood flow regulation in the healthy and ischemic 
brain,11 exhibit pericytes with swollen nuclei and deposits of 
granular osmiophilic material within the basement membrane 
between the pericytes and endothelial cells12; accumulation of 
mutated NOTCH3 proteins in pericyte membranes may also 
alter the function of the endothelial lining
Endothelial nitric oxide (NO) has a crucial role in the cerebral 
circulation linking cerebrovascular function with cognition.13 NO 
is synthesized in the endothelium in a process that involves the 
enzyme endothelial NO synthase (eNOS), the substrate arginine, 
and the essential enzyme cofactor tetrahydrobiopterin (BH4).14 
Increased NO bioavailability through eNOS activation preserves 
cerebral blood flow, prevents inflammation, platelet aggregation, 
thrombosis, and apoptosis.13 NO has been suggested to exert 
paracrine effects on neuronal and microglial cells and plays a 
critical role in mediating dilation of brain capillaries by affect-
ing active pericyte relaxation.11 Stabilization of eNOS activity, 
by enhancing its substrate, cofactors, and transcription, improves 
NO bioavailability and endothelial function. Decreased BH4 bio-
availability results in functional NOS uncoupling,15,16 impaired 
vascular relaxation, and endothelial dysfunction (ED). ED occurs 
in the cerebral circulation in association with vascular-related dis-
eases that include stroke and Alzheimer’s disease and has been 
correlated with increased risk of acute ischemic stroke.17
Flow-mediated dilation, the response of the endothelium to 
shear stress evoked by reactive hyperemia (RH), is a useful 
test to detect abnormalities in NO production in the vascu-
lar wall using different techniques.18,19 Patients with lacunar 
infarcts show impaired flow-mediated dilation by brachial 
artery ultrasound,20 a measure of conduit artery vasodilation.
Previous studies in CADASIL patients described impaired 
vasoreactivity both in the cerebral21,22 and peripheral cir-
culation.23–26 However ED was shown in resistance arteries, 
but not in conduit vessels.24 Flow perturbance by mutated 
NOTCH3 proteins in capillary pericytes may largely mediate 
impaired vasoreactivity and pathophysiology of brain damage 
in CADASIL. Therefore, a method that tests microvascular, 
rather than conduit artery, reactivity is appropriate to investi-
gate treatment effects in this population.
Peripheral arterial tonometry (PAT), a novel noninvasive, 
quantitative, and repeatable test that measures changes in 
digital pulse volume during RH, evaluates the endothelial 
function of resistance arteries and NO-mediated changes in 
microvascular response. PAT accurately assesses variations 
with increasing risk factor burden and targeted treatment27,28 
and is independently associated with incident cardiovascular 
(CV) events in high risk patients.29
An impaired RH-PAT (reactive hyperemia index by periph-
eral arterial tonometry) response has been observed early after 
acute cerebrovascular events, including stroke30 and subarach-
noid hemorrhage,31 and was found to be independently asso-
ciated with fewer delirium/coma-free days in patients with 
critical illness.32 RH-PAT has been shown to be sensitive to 
treatment effects in patients with diabetes mellitus and coro-
nary artery disease.33,34
In a small correlative study, both cerebral blood flow and 
peripheral vasodilation by RH-PAT were reduced in CADASIL 
patients.35 As NO has a fundamental role in cerebral blood flow 
regulation and small vessel damage, with impaired endothelial 
integrity, is the pathological hallmark of CADASIL, ameliora-
tion of endothelial function is an end point relevant to disease 
pathophysiology. Exogenous BH4 administration can improve 
vascular NO bioavailability by reversing eNOS uncoupling and 
was shown to acutely restore endothelial function in patients 
with CV risk factors or overt coronary artery disease.36
Aim of the present study was to assess whether chronic admin-
istration of the BH4 analog sapropterin (6R-BH4) improves 
endothelium-dependent vasodilation in CADASIL patients.
Methods
Participants
Adult patients aged between 30 and 65 years, with CADASIL with 
or without previous neurological symptoms or cerebrovascular events, 
were eligible for screening. The diagnosis had to be confirmed by the 
identification of a NOTCH3 gene mutation. Patients were required to 
have a recent (within 6 months) cranial MRI consistent with CADASIL, 
which was done for study purposes if not already available.
Exclusion criteria were dementia with a score <33 at the Structured 
Interview for the Diagnosis of Dementia instrument; autoimmune dis-
orders; pregnancy, nursing or childbearing potential not on adequate 
contraception; recent (within 3 months before screening) myocardial 
infarction, cerebrovascular accident, or pulmonary embolism; severe 
uncontrolled hypertension (arterial blood pressure [BP] >180/110 
mm Hg); hypotension at screening, defined as seated resting values 
of <100 mm Hg systolic or <55 mm Hg diastolic, or symptomatic 
hypotension; serum creatinine >2.5 mg/dL or hepatic enzymes >2× 
normal; and concomitant treatment with methotrexate, levodopa, 
phosphodiesterase-3 or -5 inhibitors, pentoxyfylline, nitrate/nitrite-
based vasodilators, L-arginine, or gingko biloba.
Patients were recruited, after providing written informed consent, 
at 5 national referral centers for CADASIL management. The study 
was done according to the Declaration of Helsinki and subsequent 
revisions. The study is registered under the EudraCT number 2007-
004370-55 and was approved by the ethics committees of each par-
ticipating center.
Randomization and Masking
Treatment allocation was managed by a logistic manager at the co-
ordinating center using a computer-generated, 1:1 randomization 
scheme with a sequential block size of 4 for each clinical center and 
assigning a randomization code to each subject after screening and 
confirmation of eligibility. The trial drug or matching placebo was 
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packed in identical masked bottles marked with the patient’s identi-
fication number. Patients, their families, the investigators, the study 
manager, and statistician were masked to treatment assignment.
Procedures
This was a multicenter, phase II, randomized, double-blind, paral-
lel-group, placebo-controlled trial planned to include 60 subjects. 
Consenting patients entered a 3-month run-in phase to confirm sta-
bility on optimized concomitant treatment. Baseline evaluation in-
cluded history, clinical and neurological evaluation, determination of 
the modified National Institutes of Health Stroke Scale (mNIHSS) 
to assess neurological status and the Barthel index and the modified 
Rankin scale to assess disability, blood sampling for routine labora-
tory tests, and a vasoreactivity study.
Patients received sapropterin dihydrochloride, a pharmaceutical 
formulation of BH4, provided in 100 mg fast-dissolving tablets or 
matching placebo for 24 months. The drug was given in doses of 200 
or 400 mg BID, according to body weight ≤ or >60 kg, corresponding 
to ≈5 mg/kg/day, and were selected based on previous studies of BH4 
in subjects with ED and CV risk factors or diseases. Patients were in-
structed to dissolve tablets in water and take them with food twice a day.
After 1, 2, 4, and 6 months, and every 6 months thereafter, a clini-
cal assessment was performed and blood was sampled for safety 
laboratory measurements (complete blood count, aspartate amino-
transferase, alanine aminotransferase, γ-glutamyl transferase, serum 
bilirubin, and creatinine). After 24 months, baseline assessments were 
repeated. Treatment compliance was calculated from tablet count for 
each interval between visits as the percentage of the dispensed study 
medication taken by the patient.
Study End Points
The primary efficacy end point was the change in endothelium-de-
pendent vasodilation as assessed by RH-PAT after 24-month dou-
ble-blind treatment with sapropterin or placebo. Secondary efficacy 
end points included changes in neurological status by the modified 
National Institutes of Health Stroke Scale and changes in the disabil-
ity scores Barthel index and modified Rankin scale.
Safety measurements included adverse events, vital signs, and 
laboratory profile.
Assessment of Endothelial Function
Vasoreactivity studies were performed at the 5 clinical centers by 2 
trained investigators. Vasodilation after RH was assessed in the morning 
in the fasting state using the Endo-PAT 2000 appliance (Itamar, Cesarea, 
Israel).28,37 The patient lied down comfortably with hands supported at 
approximately heart level in room with dim lights and controlled 24°C 
temperature. A cuff was placed on the nondominant upper arm, whereas 
the contralateral served as control. BP and heart rate were measured 
before starting the test from the patient’s control arm. After a 10-minute 
equilibration period, the cuff was inflated to 60 mm Hg above systolic 
pressure for 5 minutes and then deflated to induce RH, whereas signal 
recording was continued for 10 minutes. RH-PAT was automatically 
calculated as operator-independent ratio of the average post- and preoc-
clusion amplitude of the signal, normalized by the control arm.
To exclude an interday variability and to ensure within-subject re-
peatability, basal levels of RH-PAT were measured in the morning in a 
group of fasted volunteers (n=9), on 2 consecutive days. Consistently 
with previous reports,38 average data obtained did not demonstrate an 
interday effect on vascular function (RH-PAT 2.05±0.29 for day 1 and 
2.04±0.27 for day 2; P=0.94, coefficient of variation 4.67%).
No vasoreactivity study was considered inadequate after blinded 
assessment before database locking.
Statistical Analysis
The number of patients per group needed to detect an absolute differ-
ence between active treatment and placebo after 24 months in RH-
PAT of 1.8 with a power of 90%, with a 2-tailed t test at the 5% level 
and standard deviation of 2 was calculated to be 26. To account for a 
15% drop-out rate, 61 patients were randomized.
All analyses were done in 2 study populations: the intention-to-
treat (ITT) and the per-protocol population (PP). The ITT population 
included all patients randomly assigned to treatment and assessed us-
ing the last-observation-carried-forward method; as sensitivity analy-
sis, we also imputed data that were missing at follow-up using the 
multiple imputation method, created 5 complete data sets, analyzed 
each data set, and pooled the results. The PP population included pa-
tients who did not discontinue treatment until the 24-month visit and 
had a treatment compliance ≥80%.
Continuous variables are presented as median (interquartile range) 
and categorical variables as numbers and percentages. For categori-
cal data, groups were compared by contingency tables with the χ2 or 
Fisher exact test, where appropriate. Continuous data were analyzed 
using a 2-sided Student’s t test, after checking data normal distribu-
tion (based on the Shapiro–Wilk statistic) and a 2-sided Wilcoxon’s 
rank sum test otherwise.
To analyze differences between treatment arms in terms of im-
proved endothelial function (change from baseline in RH-PAT at 
end of study >0), odds ratios and the corresponding 95% confidence 
intervals (CI) were obtained using unconditional multiple logistic 
regression, adjusted for prespecified subgroups of interest based on 
age, sex, presence of any CV risk factors, history of cerebrovascular 
events, duration of symptoms, and concomitant treatment with drugs 
active on endothelial function.
All statistical analyses were done with significance set at the 5% 
level and using 2-sided tests or 2-sided 95% CI, using SAS version 
9.1 (Cary, NC, USA).
Results
Patients were enrolled from January 3, 2008, till March 20, 
2009; follow-up was completed on April 2011. The number 
of subjects enrolled and their fate in the study are shown in 
Figure. Sixty-one subjects from 38 different families were 
ultimately randomized, 32 to sapropterin and 29 to placebo, 
and are included in the ITT population. Six of the random-
ized patients dropped out at different times during the study 
(Figure); in no case was the study code broken. Overall, 50 
patients, 29 in the sapropterin and 21 in the placebo arm, com-
pleted the study with a treatment compliance ≥80% and were 
included in the PP analysis.
Demographics, neurological history, concomitant drug 
therapy, and other baseline characteristics of the ITT popula-
tion are shown in Table 1. Despite randomization, male sex 
and risk factors were more common in the placebo group; 
however, BP, lipid, and glucose profile overlapped between 
groups. Treatment with drugs known to favorably affect endo-
thelial function (calcium channel blockers, rennin–angioten-
sin system inhibitors, or statins) was common, but the overall 
proportion of subjects who took ≥1 of these drugs was similar 
between treatment arms. Disability was mild in most subjects, 
with patients on sapropterin showing lower scores than those 
on placebo. Overall, 20 subjects (33%), 10 in each treatment 
arm, showed baseline RH-PAT values below the 5th percentile 
of a normal control group, indicative of established ED.
We found no significant difference in the study primary end 
point, RH-PAT change from baseline at 24 months, between 
patients assigned sapropterin and those assigned placebo either 
in the ITT or in the PP population (Table 2). In both data sets, 
changes in RH-PAT between baseline and end of treatment 
did not achieve statistical significance either in subjects in the 
sapropterin arm (ITT, P=0.67; PP, P=0.45) or in those on pla-
cebo (ITT, P=0.29; PP, P=0.18; Table 2). Among patients who 
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completed the study, RH-PAT values indicative of ED were 
found in 30% in the sapropterin and 65% in the placebo arm.
The proportion of patients with worsened neurological sta-
tus or disability scores, expressed as any increase in modified 
National Institutes of Health Stroke Scale and modified Rankin 
scale scores or any decrease in Barthel index, did not differ 
between treatment arms either in the ITT or in the PP population 
(Table 3).
RH-PAT increased after 24 months in 37% of subjects 
on sapropterin versus 28% of patients on placebo. By mul-
tivariable logistic regression (Table 4), after adjustment for 
demographic and clinical characteristics, no association was 
observed between treatment arm and improved RH-PAT (odds 
ratio, 2.42; 95% CI, 0.72, 8.14).
The proportion of patients with treatment-emergent adverse 
events was similar between groups (50% on sapropterin ver-
sus 48.3% on placebo; Table 5). No death occurred. Serious 
adverse events were reported in 2 (6.3%) patients assigned to 
sapropterin and in 4 (13.8%) patients assigned to placebo, 2 
of whom discontinued treatment. Overall, 34 adverse events 
developed during the treatment period in >5% of patients, 18 
in 16 patients on sapropterin and 16 in 15 patients on placebo; 
the nature of the event was in most cases consistent with dis-
ease progression (Table I in the online-only Data Supplement). 
Generally, adverse events were mild to moderate and resolved 
without the need to discontinue study medication.
Discussion
 Vasomotor function seems to be a key pathogenetic mechanism 
that underlies the phenotypic manifestations of CADASIL, 
a rare disease for which no specific treatment is currently 
available. We report here the first randomized, controlled, 
double-blind trial of treatment targeting endothelial function in 
patients with confirmed CADASIL. In this phase II multicenter 
study, supplementation with sapropterin, an analog of BH4, 
essential cofactor of eNOS in NO synthesis, did not improve 
the primary end point, endothelium-dependent vasodilation.
The rationale for targeting endothelium-dependent vasodila-
tion in CADASIL rests on the molecular mechanisms of the 
disease, NOTCH3 accumulation in vascular smooth muscle 
cells cytoplasmic membrane and within the basement mem-
brane of capillaries between the pericytes and endothelial cells, 
on previously reported morphological abnormalities in endo-
thelial cells and laboratory alterations of endothelial function 
in CADASIL patients,1,23–25,39 and on the association between 
biomarkers of endothelial function and the clinical pheno-
type.40 RH-PAT expresses microvascular function, and its cor-
relation with cerebral blood flow35 in patients with CADASIL 
suggests that characterization of peripheral vascular function 
may represent a convenient, although indirect, marker of brain 
vascular function, potentially useful to limit the number of 
patients needed in therapeutic studies addressing the onset and 
progression of clinical manifestation of CADASIL.
As to minimize the confounding effects of ageing on endothe-
lial function, we limited recruitment to patients <65 years, our 
population had a mean age of 45.5 years, which corresponds to 
the reported average at the clinical onset of CADASIL symp-
toms in the literature.1 Consistently with this early stage of overt 
disease, we observed an unsurprisingly low frequency of new 
cerebrovascular events (3.3/100 person-years) during the study, 
less than one-third of the average overall incident stroke rate, that 
supports our choice of a surrogate end point for treatment effect.
As in previous reports,40 overall 54% of our CADASIL sub-
jects had ≥1 CV risk factor. CV risk factors damage endo-
thelial cells lowering NO bioavailability and, although ED 
Figure. Trial flow diagram. ITT indicates intention-to-
treat; and PP, per-protocol population.
 by guest on September 25, 2014http://stroke.ahajournals.org/Downloaded from 
De Maria et al  Sapropterin and Vasoreactivity in CADASIL Patients   2963
can develop throughout the entire vascular tree, the circula-
tion of the brain may be particularly susceptible to it.41 CV 
risk factors can exacerbate disease progression in CADASIL 
patients: Singhal et al42 found an association between smoking 
and age at onset of lacunar infarcts, whereas Adib-Samii et al43 
observed an increased risk of ischemic stroke in hypertensive 
and smoker CADASIL patients. BP, lipid, and glucose profile 
were similar in the 2 treatment arms.
After 24 months, no between-group difference in RH-PAT, 
our primary end point, achieved statistical significance. 
Furthermore, by multivariable logistic regression, no clinical 
or treatment variable was a significant predictor of improved 
RH-PAT at the end of study.
Several hypotheses should be considered to explain these 
negative findings.
The administered drug dose may have been too low to 
exert relevant effects on endothelial function. Sapropterin, 
the BH4 formulation used in this trial, is approved for treat-
ment of hyperphenylaninemia at a recommended dose of 10 
mg/kg/day. BH4 exerts vasodilating effects through enhanced 
NO synthesis and may decrease BP.44 We chose doses in the 
range previously used in studies of chronic BH4 supplemen-
tation in patients with hypercholesterolemia (400 mg BID45) 
or ischemic heart disease (400–700 mg QD46) to achieve daily 
averages of 5 mg/kg. These doses were deemed safe to avoid 
excessive BP decrease in CADASIL patients, who frequently 
Table 1. Baseline Characteristics
Sapropterin, 
n=32
Placebo,  
n=29
Male sex 15 (47%) 18 (62%)
Age, y 46 (8) 45 (9)
Body mass index, kg/m2 27 (4) 28 (5)
Systolic blood pressure, mm Hg* 118 (10) 124 (15)
Diastolic blood pressure, mm Hg* 77 (10) 80 (10)
Heart rate, bpm 70 (10) 67 (10)
Neurological history
  Migraine 7 (22%) 10 (35%)
  Epilepsy 1 (3%) 5 (17%)
  Psychiatric disturbances 5 (17%) 6 (22%)
  Vision disturbances … 4 (14)
  Gait disturbances 6 (19%) 7 ((24%)
  Previous stroke 7 (22%) 9 (31%)
  Number of strokes* 2.3 (1.5) 2.4 (1.6)
  Previous TIA 5 (16%) 12 (41%)
  Number of TIAs* 2.2 (1.8) 2.6 (2.8)
  Previous TIA and stroke 12 (37%) 18 (62%)
  Years since symptom onset* 7 (9) 7 (7)
  Age at symptom onset 37 (12) 37 (10)
  Cardiovascular risk factors (≥1) 16 (50%) 17 (59%)
  Current smoker 8 (25%) 8 (28%)
  Hypertension 3 (10%) 8 (28%)
  Hypercholesterolemia 8 (25%) 9 (31%)
  Diabetes mellitus … 2 (7%)
Biochemistry
  Total cholesterol (mmol/L)* 5.22 (0.83) 4.96 (0.90)
  HDL-cholesterol (mmol/L)* 1.40 (0.34) 1.34 (0.41)
  LDL-cholesterol (mmol/L)* 3.20 (0.80) 3.00 (0.93)
  Triglycerides (mmol/L)* 1.29 (0.67) 1.17 (0.53)
  Fasting glucose (mmol/L)* 4.55 (0.66) 4.93 (0.77)
  Creatinine (mmol/L)* 71.3 (13.2) 73.9 (17.6)
Drug treatment
  Antiplatelet agents 23 (72%) 23 (79%)
  Statins 4 (12%) 8 (28%)
  Calcium channel blockers 7 (22%) 4 (14%)
  RAS inhibitors 6 (19%) 6 (21%)
  Any drug active on endothelial  
function†
13 (41%) 11 (38%)
  Antiepilepsy agents 2 (6%) 6 (21%)
  Antidepressants 3 (9%) 3 (10%)
Neurological status and disability scales
  mNIHSS >1 4 (12%) 4 (14%)
  Barthel index ≤80 1 (3%) 2 (7%)
  mRs >1 (disabled) 4 (12%) 4 (14%)
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; mNIHSS, 
modified National Institute of Health Stroke Scale; mRS, modified Rankin scale; 
RAS, renin–angiotensin-system; and TIA, transient ischemic attack.
*Non-normal distribution. †composite of calcium channel blocker, RAS-
inhibitor or statin.
Table 2. Primary Efficacy End Point in the Intention-to-Treat 
and Per Protocol Populations
Baseline
End of  
Study
Between-Group  
Differences vs 
Placebo (95% CI) P Value
Intention-to-treat 
population
0.19 (−0.18, 0.56) 0.914
  Sapropterin, n=32 2.13 (0.63) 2.16 (0.70)
  Placebo, n=29 2.01 (0.56) 1.85 (0.47)
Per-protocol population 0.25 (−0.19, 0.70) 0.798
  Sapropterin, n=29 2.11 (0.65) 2.12 (0.72)
  Placebo, n=21 2.01 (0.60) 1.76 (0.41)
P values are for Wilcoxon rank sum test to compare changes from baseline. 
CI indicates confidence interval.
Table 3. Proportion of Patients With Worsened Neurological 
Status and Disability Scales
mNIHSS
Barthel 
Index mRS
Intention-to-treat population
  Sapropterin, n=32 3 (10) 3 (9) 7 (22)
  Placebo, n=29 4 (14) 2 (7) 4 (14)
  P value 0.925 1.000 0.627
Per-protocol population
  Sapropterin, n=29 2 (7) 2 (7) 6 (21)
  Placebo, n=21 4 (19) 2 (10) 3 (14)
  P value 0.223 1.000 0.716
mNIHSS indicates modified National Institute of Health Stroke Scale; and 
mRS, modified Rankin scale.
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show relative hypotension47; reduction of already low average 
BP levels could contribute to decreased cerebral blood flow, 
further white matter damage, and potential cognitive deteriora-
tion. At this dose, sapropterin was remarkably safe, with no 
excess adverse events nor unfavorable BP changes. In fact, 
although BP values of ≥130 mm Hg were found in 38% of our 
patients at baseline, average levels in our CADASIL patients 
(121±13 mm Hg) were lower than the means reported in other 
chronic sapropterin trials in healthy hypercholesterolemic sub-
jects (129.5±8.5 mm Hg)45 or ischemic heart disease patients 
before coronary artery bypass grafting (>132 mm Hg).46 A dose 
up–titration schedule based on BP response to a 5 mg/kg chal-
lenge might have allowed to safely reach 10 mg/kg averages 
and to evidence the potential benefit of higher doses.
Also, a ceiling effect might have occurred; although one-
third of our CADASIL patients showed definite ED, overall 
baseline RH-PAT values were higher than expected. Actually 
among patients with ≥1 CV risk factors, average baseline 
RH-PAT was 1.89±0.45 and post-treatment RH-PAT was sig-
nificantly higher on sapropterin (2.22±0.82) than on placebo 
(1.77±0.44; P=0.037). The inclusion of patients with more 
advanced disease might have led to evidence of benefit.
Lack of efficacy might also be because of aspects of BH4 
pharmacokinetics and pharmacodynamic that are currently 
incompletely appreciated. BH4 is easily oxidized, thermo and 
photo labile, and poorly diffusible through the cell membrane. 
Although sapropterin has overcome many of these problems, 
for example, through the incorporation of ascorbic acid as 
excipient to prevent autoxidation, bioavailability with chronic 
administration might still have been limited. The ultimate 
intent of oral supplementation is the elevation of BH4 within 
endothelial cells. However, the determinants of intracellular 
BH4 concentration are complex16,37 and include the anabolism, 
catabolism, and recycling of BH4 by dihydrofolate reductase, 
the enzyme that regenerates BH4 from BH2 inside cells. 
Whether dihydrofolate reductase activity is preserved in the 
endothelium of diseased blood vessels is poorly understood.
Treatment duration, the longest to date reported in pub-
lished CV studies of oral BH4 supplementation, that ranged 
from 1 to 8 weeks,45,46,48 might represent another factor in lack 
of efficacy. Chronic BH4 administration has been suggested 
to determine accumulation of BH2 in endothelial cells, with 
competitive replacement of eNOS-bound BH4, eNOS uncou-
pling, and diminished BH4 efficacy.48
Study Limitations
Our study has certain limitations. Although the trial cohort 
was relatively large for a rare disease, such as CADASIL, the 
study population was, as a result of the eligibility criteria, rela-
tively young and too small to investigate clinical progression.2 
However, we planned the study and sample size to assess a 
surrogate end point, endothelial function, validated in other 
CV diseases. Long-term assessment of the effect of endothe-
lial function on the incidence and timing of new cerebrovas-
cular events in preclinical or mildly symptomatic patients may 
be useful to target treatments, but enrollment in prospective 
clinical trials of large populations with rare diseases, such as 
CADASIL, remains a major challenge.3
We did not evaluate the effect of sapropoterin on cogni-
tive function, a main and common source of disability in 
CADASIL. However, no association of vasoreactivity with 
cognitive performance has been previously reported.35
The sensitivity to treatment effects of PAT has been vali-
dated in CV disease but not in CADASIL; however, there is no 
Table 5. Number of Patients With Adverse Events After 
Treatment Start
Sapropterin  
(n=32), n (%)
Placebo  
(n=29), n (%) P Value
Patients who reported adverse events
  No 16 (50.0) 15 (51.7)
  Yes 16 (50.0) 14 (48.3) 1.000
  1 3 (9.4) 2 (6.9)
  2 6 (18.7) 6 (20.7)
  ≥3 7 (21.9) 6 (20.7)
Patients who reported serious adverse events
  No 30 (93.7) 25 (86.2)
  Yes 2 (6.3) 4 (13.8) 0.410
  1 1 (3.1) 3 (10.3)
  2 0 1 (3.5)
  ≥3 1 (3.1) 0
Patients who reported ischemic cerebral infarction
  No 31 (96.9) 28 (96.5)
  Yes 1 (3.1) 1 (3.5) 1.000
Table 4. Multivariable Analysis of Factors Associated to 
Improved RH-PAT at End of Study
RH-PAT Stable/Worsened Improved OR 95% CI
Covariate n=41 (67%) n=20 (33%)
  Age at baseline  
(years)
47 (39–52) 46 (41–48) 0.972 (0.896, 1.053)
Sex
  Male 23 (56) 10 (50) 1 (ref.) …
  Female 18 (44) 10 (50) 1.362 (0.410, 4.527)
  Duration of 
symptoms
3 (0–9) 5 (1–12) 1.014 (0.946, 1.087)
Cardiovascular risk factors
  0 19 (46) 9 (45) 1 (ref.) …
  ≥1 22 (54) 11 (55) 1.023 (0.305, 3.437)
Cerebrovascular events
  0 21 (51) 10 (50) 1 (ref.) …
  ≥1 20 (49) 10 (50) 1.293 (0.358, 4.674)
Any drug active on endothelial function*
  0 26 (63) 11 (55) 1 (ref.) …
  ≥1 15 (37) 9 (45) 1.679 (0.460, 6.120)
Treatment arm
  Placebo 21 (51) 8 (40) 1 (ref.) …
  Sapropterin 20 (49) 12 (60) 1.757 (0.547, 5.649)
Odds ratios (OR) from multivariate logistic regression of improved RH-PAT 
at end of study and corresponding 95% confidence intervals (CI), including 
terms for all covariates shown. RH-PAT indicates reactive hyperemia index by 
peripheral arterial tonometry.
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intervention for CADASIL against which it could have been 
validated.
Many patients were taking ≥1 drug known to improve endo-
thelial function. Statins alone have significant beneficial direct 
effects on BH4 bioavailability through upregulation of guano-
sine triphosphate cyclohydrolase-1 (the rate-limiting enzyme 
in BH4 synthesis) expression and activity. Calcium channel 
blockers or rennin–angiotensin system inhibitors also have 
vessel wall-protective and antioxidant properties. Although 
drug distribution was balanced across treatment arms at base-
line, after 24 months, more subjects who completed the study 
were on vasoprotective drugs in the placebo arm (44%) than 
in the active treatment group (34%). It has been suggested46 
that patients naïve to vasoprotective drugs may have greater 
eNOS reserve, hence, show greater improvement in endothe-
lium-dependent vasodilation with sapropterin than subjects 
who already take such therapies. Among our patients who took 
drugs active on endothelial function, after 24 months, RH-PAT 
was higher on sapropoterin than on placebo (2.28 [0.99] versus 
1.73 [0.42], P=0.082, respectively). The proportion of patients 
with ED at the end of study was double in the placebo arm. This 
finding suggests that, even in patients on antioxidant drugs, a 
progressive deterioration of endothelial function occurred on 
placebo that might be delayed by sapropterin.
The last-observation–carried forward method used to impute 
missing values for the ITT population may introduce bias; 
however, the findings were replicated both using a different 
method to account for missing values and in the PP population.
Clinical Implications
CADASIL has been considered a model of sporadic small ves-
sel disease (SVD), with a common specific pattern of progres-
sive vascular cognitive impairment.49,50
SVD is strongly associated with aging, diabetes melli-
tus, and hypertension, a cumulative risk factor burden that 
strongly affects endothelial function. The theoretical benefits 
of improved NO bioavailibility in SVD are supported by the 
efficacy of NO modulators in secondary stroke prevention tri-
als.51,52 Tolerability of agents with vasodilating properties in 
SVD patients is suggested by findings of the SPS3 trial,53 where 
achievement of lower target BP was associated with significant 
reductions in intracerebral hemorrhage, stroke, and few serious 
side effects. Sapropterin, a NO modulator, was well tolerated 
at low doses in our CADASIL population with normal–low 
BP values. Because of the prevalence and effect of SVD, with 
which CADASIL shares structural microvascular damage, the 
exploration of the potential benefits of sapropterin over and 
above current vasoprotective drugs, with appropriate dose- 
finding designs, may be warranted and safe in SVD patients 
with borderline or high-normal BP.
Conclusions
In this phase II–randomized, double-blind, placebo-controlled 
trial, sapropterin, an analog of BH4 that increases NO bio-
availability, was not effective on endothelium-dependent 
vasodilation. Sapropterin was safe and well-tolerated at the 
average dose of 5 mg/kg/day.
The finding of worsening endothelium-dependent vasodila-
tion over 2 years during placebo treatment warrants further 
investigation of the relation of endothelial function to disease 
progression in CADASIL patients.
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Table I Distribution of adverse events affecting >5% of patients
Sapropterin
 (n=18)
Placebo 
(n=16)
Transient Neurologic deficit 6 6
Headache 3 4
Migraine 2 4
Depressive symptoms 3 -
Ischemic cerebral infarction 2 2
Near fainiting 2 -
